Evidence map›Paper›PMID 40750989›Full record

ArticleScientific reports2025

STELLA provides a drug design framework enabling extensive fragment-level chemical space exploration and balanced multi-parameter optimization.

Hokyun Jeon, Jin Gyu Lee, Wonseok Shin, Hyunjun Ji, InSuk Joung, Hui Sun Lee

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hokyun JeonStandigm Inc, 182 Dogok-ro, Gangnam-gu, Seoul, South Korea.
Jin Gyu LeeStandigm Inc, 182 Dogok-ro, Gangnam-gu, Seoul, South Korea.
Wonseok ShinStandigm Inc, 182 Dogok-ro, Gangnam-gu, Seoul, South Korea.
Hyunjun JiStandigm Inc, 182 Dogok-ro, Gangnam-gu, Seoul, South Korea.
InSuk JoungStandigm Inc, 182 Dogok-ro, Gangnam-gu, Seoul, South Korea. insuk.joung@standigm.com.
Hui Sun LeeStandigm Inc, 182 Dogok-ro, Gangnam-gu, Seoul, South Korea. huisun.lee@standigm.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In drug discovery, identifying molecules with desired pharmacological properties remains challenging, as conventional methods often rely on exhaustive trial-and-error and limited exploration of chemical space. Here, we present STELLA, a metaheuristics-based generative molecular design framework that combines an evolutionary algorithm for fragment-based chemical space exploration with a clustering-based conformational space annealing method for efficient multi-parameter optimization. Additionally, it leverages deep learning models for accurate prediction of pharmacological properties. Our case study, which focuses on docking score and quantitative estimate of drug-likeness as primary objectives, demonstrates that STELLA generates 217% more hit candidates with 161% more unique scaffolds and achieves more advanced Pareto fronts compared to REINVENT 4. In performance evaluations optimizing 16 properties simultaneously for MolFinder, REINVENT 4, and STELLA, STELLA consistently outperforms the control methods by achieving better average objective scores and exploring a broader region of chemical space. The results highlight STELLA's superior performance in both efficient exploration of chemical space and multi-parameter optimization, indicating that STELLA is a powerful tool for de novo molecular design.

Indexed as

Drug DesignDrug DiscoveryAlgorithmsDeep LearningMolecular Docking SimulationChemical space explorationDeep learningDrug discoveryEvolutionary algorithmMulti-parameter optimization

Identifiers

PMID40750989
PMCPMC12316942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.